Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 8921SC

8921SC 10 µg (With Carrier)
8921SF 10 µg (Carrier Free)
8921LC 50 µg (With Carrier)
8921LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-8 (hIL-8) Ser28-Ser99 (Accession #NM_000584) was produced in E.coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-8. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIL-8 does not have a Met on the amino terminus and has a calculated MW of 8,386. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides. The expected amino-terminal SAKEL of recombinant hIL-8 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-8 was determined by upregulation of CD11b expression on primary human neutrophils. The ED50 of each lot is between 1-5 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIL-8.


Product Usage Information

Formulation:

With carrier:

SC: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.

LC: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.

Carrier free:

SF: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2.

LF: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2.


Storage: Stable at 4°C for 1 year after receipt. Maintain sterility. Do not store frozen.

The prototypical CXC chemokine, IL-8, is best known for effects on neutrophils, specifically its ability to act as a chemoattractant and activate degranulation and respiratory burst (1,2,3).

IL-8 is produced by a number of cell types including monocytes, T cells, neutrophils, fibroblasts, endothelial cells, and others (1). In addition to its effects on neutrophils, IL-8 promotes angiogenesis, inhibits endothelial cell apoptosis, and promotes the proliferation of melanoma cells in an autocrine fashion (1). As a result, IL-8 may be a contributing factor to the development of certain cancers (1,2). There are two distinct receptors for IL-8, CXCR1 and CXCR2; both are G protein-coupled receptors (1). Ligand binding induces Ca2+ mobilization and activates the PI3K, PKC, Rho, and Rac pathways (1,3).


1.  Payne, A.S. and Cornelius, L.A. (2002) J Invest Dermatol 118, 915-22.

2.  Brat, D.J. et al. (2005) Neuro Oncol 7, 122-33.

3.  Mukaida, N. (2003) Am J Physiol Lung Cell Mol Physiol 284, L566-77.


Entrez-Gene Id 3576
Swiss-Prot Acc. P10145


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.